Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Lytix Biopharma AS ( (DE:6BG) ) is now available.
Lytix Biopharma has released its 2025 annual report, highlighting a pivotal year marked by clinical progress, strategic focus, and a clearer path toward late-stage development and commercialization of its lead oncolytic peptide, ruxotemitide. The company reported encouraging Phase II data in melanoma, including a 44% pathological complete response rate and about 90% overall pathological response in the NeoLIPA neoadjuvant study, as well as systemic immune activation and durable disease control in heavily pretreated patients in the ATLAS-IT-05 trial.
Lytix also advanced ruxotemitide in partnership with Verrica Pharmaceuticals toward a potential Phase III program in basal cell carcinoma and prepared its next-generation candidate LTX-401 for clinical entry, signaling a broader pipeline strategy. Following the reporting period, the company bolstered its financial position with a NOK 77.3 million capital raise, improving flexibility to fund development programs and strengthening its positioning as it seeks commercialization and strategic partnerships in the competitive immuno-oncology field.
More about Lytix Biopharma AS
Lytix Biopharma AS is a clinical-stage biotech company based in Oslo, Norway, focused on immuno-oncology. It develops novel immunotherapies based on oncolytic peptides that directly kill tumor cells and activate the immune system, with lead candidate ruxotemitide (formerly LTX-315) being tested across multiple solid-tumor indications, both alone and in combination with checkpoint inhibitors.
Average Trading Volume: 60,183
Current Market Cap: NOK792.1M
Learn more about 6BG stock on TipRanks’ Stock Analysis page.